Targeted therapy represents one of the major challenges in Nanomedicine, with less than 5% of the antibody-targeted vehicles reaching target cells in most cases. In this regard, apart from displaying a specific ligand, it is critical to control biodistribution upon systemic administration by using vehicles of a suitable size and biological nature to avoid being captured in undesired organs, thus increasing their circulating times. In this context, we have developed a recombinant platform for the design of protein carriers that self-assemble as nanostructured materials. These proteins consist of different domains designed to target the cargo drug to a specific cell type and subcellular compartment, but also of architectural domains that promote self-assembling as nanoparticles of regular size. The combination of these features makes our de novo-designed vehicles fully biocompatible biomaterials with controllable physical and functional properties, stable in the bloodstream.
